BiotechTube

CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Refractory or Relapsed Multiple Myeloma

Conditions

Refractory or Relapsed Multiple Myeloma

Trial Timeline

Aug 12, 2025 → Jun 25, 2029

NCT ID
NCT06952478

About CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)

CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) is a phase 3 stage product being developed by Celltrion for Refractory or Relapsed Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06952478. Target conditions include Refractory or Relapsed Multiple Myeloma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06952478Phase 3Recruiting

Competing Products

20 competing products in Refractory or Relapsed Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
Valemetostat TosylateDaiichi SankyoPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
ASP1650Astellas PharmaPhase 2
52
YM598Astellas PharmaPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
Lenvatinib + EverolimusEisaiPhase 1/2
41
perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
77
Eribulin mesilate + Irinotecan hydrochlorideEisaiPhase 1/2
41
perampanelEisaiPhase 2
52
rabeprazole sodiumEisaiPre-clinical
23
LenvatinibEisaiPhase 2
52
E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
77
E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
77
TazemetostatEisaiPhase 2
52
RufinamideEisaiPhase 3
77
Lenvatinib + Moxifloxacin 400 mg + Placebos (matched to 4 mg and 10 mg lenvatinib capsules).EisaiPhase 1
33

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85